Patents by Inventor Edward Van Den Brink

Edward Van Den Brink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240117064
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: April 11, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240076397
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 7, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230399414
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: December 14, 2023
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D.CHAMULEAU, Tuna MUTIS
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20230321261
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: September 30, 2022
    Publication date: October 12, 2023
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20230312693
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 5, 2023
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO, Jeffrey B STAVENHAGEN
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20230159643
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Soren Christensen, Jan Egebjerg, Amout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20230087745
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 23, 2023
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ, Edward VAN DEN BRINK, Dennis VERZIJL
  • Agent, uses and methods for treatment
    Patent number: 11548950
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: January 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11542323
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: January 3, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B Stavenhagen
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11524995
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: December 13, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergström, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B. Stavenhagen
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11512137
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 29, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 11459395
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 4, 2022
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van den Brink, Dennis Verzijl
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11421024
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: August 23, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220251231
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: November 23, 2021
    Publication date: August 11, 2022
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11396553
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: July 26, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210355232
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 18, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • AGENTS, USES AND METHODS FOR TREATMENT
    Publication number: 20210292414
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Application
    Filed: December 11, 2020
    Publication date: September 23, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren, Esben Trabjerg, Kasper Dyrberg Rand
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20210269524
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: November 13, 2020
    Publication date: September 2, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11034772
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: June 15, 2021
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
    Publication number: 20210147522
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: August 27, 2020
    Publication date: May 20, 2021
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO